Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL1113 PK and Safety Study in Healthy Subjects
NCT07568652Phase 1Completed
- Sponsor
- Hanlim Pharm
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in hypertension (HTN) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hanlim Pharm. Primary endpoint: Maximum Observed Plasma Concentration at 48 hours. Started Oct 2024; status: completed.
02
Conditions
hypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07568652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07568652.